Current management of newly diagnosed acute promyelocytic leukemia

Annals of Oncology

Volumn 27, Issue 8, 2016, Pages 1474-1481

  Cicconi, L ^a   Lo Coco, Francesco ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Arsenic trioxide; PML RARA

Indexed keywords

ARSENIC TRIOXIDE; CD11B ANTIGEN; CD14 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CYTARABINE; D DIMER; DAUNORUBICIN; FRESH FROZEN PLASMA; HLA DR ANTIGEN; IDARUBICIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MITOXANTRONE; RETINOIC ACID; STEM CELL FACTOR RECEPTOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

ANTIGEN EXPRESSION; BONE MARROW SUPPRESSION; BRAIN PSEUDOTUMOR; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER REGRESSION; CANCER RISK; COHORT ANALYSIS; CRYOPRECIPITATE; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; FAILURE FREE SURVIVAL; FLOW CYTOMETRY; GENE REARRANGEMENT; HUMAN; HYPERLEUKOCYTOSIS; LEUKOCYTOSIS; LIVER TOXICITY; OVERALL SURVIVAL; PARTIAL THROMBOPLASTIN TIME; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSPECTIVE STUDY; PROTHROMBIN TIME; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINOIC ACID SYNDROME; REVIEW; TREATMENT OUTCOME; ADVERSE DRUG REACTION; PATHOLOGY;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRETINOIN;

EID: 84984981926     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw171     Document Type: Review

References (63)

1. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111(5): 2505-2515.
2. Lallemand-Breitenbach V, Guillemin MC, Janin A et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999; 189(7): 1043-1052.
3. Mistry AR, Pedersen EW, Solomon E et al. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev 2003; 17: 71-97.
4. de Thé H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010; 10(11): 775-783.
5. Sant M, Allemani C, Tereanu C et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116(19): 3724-3734.
6. Hillestad LK. Acute promyelocytic leukemia. Acta Med Scand 1957; 159: 189-194.
7. Bernard J, Mathe G, Boulay J et al. Acute promyelocytic leukaemia: a study made on 20 cases. Schweiz Med Wochenschr 1959; 89: 604-608.
8. Bernard J, Weil M, Bioron M et al. Acute promyelocytic leukaemia. Results treatment with daunorubicin. Blood 1973; 41: 489-496.
9. Avvisati G, Mandelli F, Petti MC et al. Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA. Eur J Haematol 1990; 44: 257-260.
10. Sanz MA, Jarque I, Martín G et al. Acute promyelocytic leukemia. Therapy results and prognostic factors. Cancer 1988; 61(1): 7-13.
11. Huang M, Yu-Chen Y, Shu-Rong C et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1998; 72: 567-572.
12. Castaigne S, Chomienne C, Daniel MT et al. All-trans retinoic acid as differentiating therapy for acute promyelocytic leukemias. Clinical results. Blood 1990; 76: 1704-1709.
13. Warrell RP, Frankel SR, Miller WH et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N Engl J Med 1991; 324: 1385-1393.
14. Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol 2011; 29(5): 495-503.
15. Sanz MA, Lo Coco F, Martìn G et al. Definition of relapse risk of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1253.
16. Lo-Coco F, Avvisati G, Vignetti M et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010; 116(17): 3171-3179.
17. Sanz MA, Montesinos P, Rayòn C et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with additional cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010; 115(25): 5137-5146.
18. Chen SJ, Zhou GB. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 2011; 117 (24): 6425-6437.
19. Estey E, Garcia-Manero G, Ferrajoli A et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006; 107(9): 3469-3473.
20. Lo-Coco F, Avvisati G, Vignetti M et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013; 369: 111-121.
21. Burnett A, Russell NH, Hills RK et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol 2015; 16(13): 1295-1305.
22. Mistry AR, Felix C, Withmarsh RJ et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005; 352(15): 1529-1538.
23. Hasan SK, Mays AN, Ottone T et al. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood 2008; 112(8): 3383-3390.
24. Breen KA, Grimwade D, Hunt BJ. The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. Br J Haematol 2012; 156(1): 24-36.
25. McCellan JS, Holbrook E, Coutre S et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica 2012; 97(1): 133-136.
26. Lehmann S, Ravn A, Carlsonn L et al. Continuing early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia 2011; 25(7): 1128-1134.
27. Park JH, Qiao B, Panageas KS et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011; 118: 1248-1254.
28. Sanz MA, Grimwade D, Tallman MS et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113(9): 1875-1891.
29. Seftel MD, Barnett MJ, Couban S et al. A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults. Curr Oncol 2014; 21: 234-250.
30. Lo-Coco F, Ammatuna E. The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment. Hematol Am Soc Hematol Educ Program 2006; 514: 156-161.
31. Paietta E. Expression of cell-surface antigens in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003; 16(3): 369-385.
32. Orfao A, Chillón MC, Bortoluci AM et al. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements. Haematologica 1999; 84 (5): 405-412.
33. Daver N, Kantarjian H, Marcucci G et al. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol 2015; 168: 646-653.
34. Grimwade D, Gorman P, Duprez E et al. Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood 1997; 90: 4876-4885.
35. van Dongen JJM, Macintyre EA, Gabert J et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual diseases. Leukemia 1999; 13: 1901-1928.
36. Falini B, Flenghi L, Fagioli M et al. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (Anti-PML). Blood 1997; 90: 4046-4053.
37. Dimov N, Madeiros JL, Kantarjian H et al. Rapid and reliable confirmation of acute promyelocytic leukaemia by immunofluorescence staining with an antipromyelocytic leukaemia antibody. Cancer 2010; 116: 369-376.
38. Feanaux P, Chastang C, Chevret S et al. A randomized comparison of all-trans retinoic acid followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 93: 4131-4143.
39. Sanz MA, Martín G, Rayón C et al. A modified AIDA protocol with anthracyclinebased consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARa-positive acute promyelocytic leukemia. Blood 1999; 94: 3015-3021.
40. Mandelli F, Diverio D, Avvisati G et al. Molecular remission in PML/RAR alphapositive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90(3): 1014-1021.
41. Sanz MA, Montesinos P, Rayón C et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010; 115(25): 5137-5146.
42. Burnett AK, Hills RK, Grimwade D et al. Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. Leukemia 2013; 27(4): 843-851.
43. Adès L, Chevret S, Roaffoux E et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006; 24: 5703-5710.
44. Montesinos P, Dìaz-Mediavilla J, Debèn G et al. Central nervous system involvement at first relapse in patients With acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica 2009; 94: 1242-1249.
45. Tallman MS, Andersen JW, Schiffer CA et al. All-trans retinoic acid in acute promyelocyic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 1997; 100: 4298-4302.
46. Avvisati G, Lo-Coco F, Paoloni F et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood 2011; 117: 4716-4725.
47. Asou N, Kishimoto Y, Kiyoi H et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARa transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 2007; 110(1): 59-66.
48. Montesinos P, Gonzalèz JD, Gonzalèz J et al. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapy. J Clin Oncol 2010; 28: 3872-3879.
49. Shen ZX, Shi ZZ, Fang J et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101(15): 5328-5335.
50. Powell BL, Moser B, Stock W et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010; 116: 3751-3757.
51. Iland HJ, Collins M, Bradstock K et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a nonrandomised phase 2 trial. Lancet Hematol 2015; 2(9): e357-e366.
52. Mathews V, George B, Chendamarai E et al. Single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 2010; 28: 3866-3871.
53. Ghavamzadeh A, Alimoghaddam K, Rostami S et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 2011; 29: 2753-2757.
54. Ravandi F, Estey E, Jones D et al. Effective treatment of acute promyelocytic leukemia with all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009; 27: 504-510.
55. NCCN (2015) NCCN guidelines "Acute myeloid leukemia", version 1.2015. National Comprehen-sive Cancer Network, Fort Washington, PA. Available at: http:// www.nccn.org/professionals/physician_gls/pdf/aml.pdf.
56. Platzbecker U, Avvisati G, Ehninger G et al. Improved outcome with ATRA-arsenic trioxide compared to ATRA-chemotherapy in non-high risk acute promyelocytic leukemia-updated results of the Italian-German APL0406 trial on the extended final series. Blood 2014; 124: 12.
57. Cheson BD, Bennett JM, Kopecky KJ et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21(24): 4642-4649.
58. Grimwade D, Jovanovic JV, Hills RK et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct preemptive arsenic trioxide therapy. J Clin Oncol 2009; 27(22): 3650-3658.
59. Diverio D, Rossi V, Avvisati G et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RAR-alpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter 'AIDA' trial. Blood 1998; 92: 784-789.
60. Frankel SR, Eardley A, Lauwers G et al. The 'retinoic acid syndrome' in acute promyelocytic leukemia. Ann Intern Med 1992; 117(4): 292-296.
61. Montesinos P, Bergua JM, Vellenga E et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009; 113(4): 775-783.
62. Sanz MA, Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood 2014; 123(18): 2777-2782.
63. Roboz GJ, Ritchie EK, Carlin RF et al. Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide. J Clin Oncol 2014; 32(33): 3723-3728.